Autres langues Johnson & Johnson Borsa Italiana

Actions

4JNJ

US4781601046

Temps réel estimé Tradegate Autres places de cotation 21:43:32 04/06/2024			Varia. 5j.	Varia. 1 janv.
135,6 ^EUR	+0,21%		-0,54%	-3,78%

17:18	J&J : essai concluant pour Carvykti dans le myélome multiple	CF
17:10	J&J : essai prometteur pour Tecvayli dans le myélome multiple	CF

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab	18:10
J&J : essai concluant pour Carvykti dans le myélome multiple	17:18
J&J : essai prometteur pour Tecvayli dans le myélome multiple	17:10
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	16:38
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	12:40
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	11:40
Borsa di Italia: Mai contenti!	08:00
J&J must pay $260 million in latest talc trial, Oregon jury says	02:36
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	03/06
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	03/06
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	03/06
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	03/06
Johnson & Johnson Completes Acquisition of Shockwave Medical	03/06
Johnson & Johnson - First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration	03/06
Johnson & Johnson Announces Longer-Term Data from the Pivotal Phase 1/2 Majestec-1 Study of TECVAYLI	03/06
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	03/06
J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	03/06
GSK blood cancer drug nearly halves risk of death in late-stage trial	02/06
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	01/06
Johnson & Johnson Announces First Data from the Phase 3 PALOMA-3 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib	31/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Joseph Wolk, CFO de J&J: Perte d'exclusivité de son médicament phare

Le 23 janvier 2024 à 18:30